The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity
Open accessAbstract
Recent guidelines recommend vancomycin trough concentrations between 15 and 20 mg/liter. In response, some clinicians increased vancomycin dosing to ≥4 g/day. Scant data are available regarding toxicities associated with higher vancomycin doses. The purpose of this study was to examine vancomycin-associated nephrotoxicity at ≥4 g/day. To accomplish the study objective, a cohort study among a random selection of patients receiving vancomycin or linezolid between 2005 and 2006 was performed. Patients were included if they (i) were ≥18 years of age, (ii) were nonneutropenic, (iii) were on therapy for >48 h, (iv) had baseline serum creatinine levels of <2.0 mg/dl, (v) did not suffer from cystic fibrosis, and (vi) had no intravenous contrast dye within the previous 7 days. For drug exposure, three treatment strata were created: standard vancomycin dose (<4 g/day), high vancomycin dose (≥4 g/day), and linezolid. Nephrotoxicity was defined as a serum creatinine increase of 0.5 mg/dl or 50%, whichever was greater, after therapy initiation. Stratified Kaplan-Meier analysis and Cox modeling were used to compare times to nephrotoxicity across groups. During the study, 246 patients on vancomycin (26 patients taking ≥4 g/day and 220 patients taking <4 g/day) and 45 patients on linezolid met the criteria. A significant difference in nephrotoxicity between patients receiving ≥4 g vancomycin/day, those receiving <4 g vancomycin/day, and those receiving linezolid was noted (34.6%, 10.9%, and 6.7%, respectively; P = 0.001), and Kaplan-Meier analysis identified significant differences in time to nephrotoxicity for the high-vancomycin-dose cohort compared to those for groups taking the standard dose and linezolid. In the Cox model, patients taking ≥4 g vancomycin/day, a total body weight of ≥101.4 kg, estimated creatinine clearance of ≤86.6 ml/min, and intensive care unit residence were independently associated with time to nephrotoxicity. The data suggest that higher-dose vancomycin regimens are associated with a higher likelihood of vancomycin-related nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V., & Bates, D. W. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090740 · Cited by 3,408
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat
Zetola, N., Francis, J. S., Nuermberger, E. L., & Bishai, W. R. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70112-2 · Cited by 791
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Recursive Partitioning in the Health Sciences
Zhang, H., & Singer, B. (1999) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3027-2 · Cited by 451
Nephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388
Fowler, Jr., Sakoulas, G., McIntyre, L. M., Meka, V. G., Arbeit, R. D., Cabell, C. H., Stryjewski, M. E., Eliopoulos, G. M., Reller, L. B., Corey, G. R., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423145 · Cited by 351
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/421092 · Cited by 332
Vancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275
Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-06 · Cited by 225
Sakoulas, G., Eliopoulos, G. M., Moellering, Jr., Novick, R. P., Venkataraman, L., Wennersten, C., DeGirolami, P. C., Schwaber, M. J., & Gold, H. S. (2003) · The Journal of Infectious Diseases · doi:10.1086/368128 · Cited by 187
Mohr, J. F., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/518451 · Cited by 185
A prospective study of adverse reactions associated with vancomycin therapy
Sorrell, T. C., & Collignon, P. J. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/16.2.235 · Cited by 175
Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence
Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518452 · Cited by 173
Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy
Sakoulas, G., Moellering, R. C., & Eliopoulos, G. M. (2006) · Clinical Infectious Diseases · doi:10.1086/491713 · Cited by 165
Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination
Goetz, M. B., & Sayers, J. F. B. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.2.325 · Cited by 145
Cimino, M. A., Rotstein, C., Slaughter, R. L., & Emrich, L. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90947-8 · Cited by 128
Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V. I., Fangtang, J. T., Martin, C. G., RAAD, I. I., Whimbey, E. E., Manzullo, E. F., & Bodey, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l · Cited by 109
Mild Nephrotoxicity Associated With Vancomycin Use
Downs, N. J. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390080053013 · Cited by 102
Tsuji, B. T., Rybak, M. J., Lau, K. L., & Sakoulas, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00671-06 · Cited by 90
Sader, H. S., Fritsche, T. R., & Jones, R. N. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01491-05 · Cited by 86
Tubulointerstitial Nephritis Due to Vancomycin
Codding, C. E., Ramseyer, L., Allon, M., Pitha, J. V., & Rodríguez, M. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80152-0 · Cited by 33
S Michail, G. V. (1998) · Scandinavian Journal of Rheumatology · doi:10.1080/030097498440886 · Cited by 28
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationCommunity-associated meticillin-resistant Staphylococcus aureus
DeLeo, F. R., Otto, M., Kreiswirth, B. N., & Chambers, H. F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61999-1 · Cited by 1,506
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citation
Metadata
- Authors
- Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-04
- Volume
- 52
- Issue
- 4
- Pages
- 1330-1336
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2152771638
- Cited by
- 574
- References
- 32
- FWCI
- 29.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.